Craig-Hallum Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $140

Craig-Hallum analyst Albert Lowe initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $140.